Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International is a commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising medicines for autoinflammatory and autoimmune diseases with significant unmet need. Its approved product, rilonacept, is an IL-1 inhibitor indicated for recurrent pericarditis.

The pipeline includes investigational monoclonal antibodies targeting IL-1 receptor signalling and GM-CSF receptor pathways across cardiovascular, dermatological and immunological indications.